- 4009 Hackney Springs Ln, Sachse, TX 75048
Karyotyping billing looks easy at first glance, but it gets complicated fast when a claim reaches a payer. Your cytogenetics lab runs a flawless chromosome analysis, the pathologist signs off, and then the reimbursement comes back short, or worse, denied outright.
In cytogenetic testing, one missing add-on code or incomplete requisition can eliminate the margin on a perfectly executed test. Many labs now rely on dedicated molecular diagnostics billing services just to keep up with the moving parts.
Here, we’ll discuss exactly how the 88230-88291 cytogenetics code family fits together, with particular attention to the core chromosome-analysis codes 88262-88291, what changed for 2026, and how your lab can protect your revenue.
Karyotyping is a laboratory technique that photographs and arranges a person’s chromosomes so a cytogeneticist can spot missing, extra, or rearranged pieces. It’s a workhorse test for prenatal diagnosis, unexplained developmental delay, infertility workups, and blood cancers like chronic myeloid leukemia.
Unlike a single-CPT lab test, karyotyping billing rarely uses just one code. Depending on the specimen, services performed, billing entity, and payer rules, a karyotyping claim may contain separate culture, chromosome-analysis, and interpretation/report services. These components should not be added automatically; each reported code must correspond to a service actually performed and supported by the documentation. If you fail to report a separately supported billable component, the lab may leave legitimate reimbursement on the table or create avoidable claim problems. That’s the root of most karyotyping billing headaches.
What is the CPT code for a karyotyping test? The simple answer to this common question is that there isn’t a single “karyotyping code.”
Karyotyping is billed using a family of CPT codes (88230-88291) that separate tissue culture, chromosome counting, and interpretation into distinct, potentially stackable line items. If you bill an unsupported or incorrect combination, Medicare, Medicaid, or a commercial payer may deny, reject, or otherwise adjust the claim.
First, let’s discuss the tissue culture codes that lead to karyotyping tests.
| CPT Code | Service | Billing Significance |
|---|---|---|
| 88230 | Tissue culture, lymphocytes | Used for appropriate lymphocyte culture services |
| 88233 | Tissue culture, skin/other solid tissue biopsy | Used for appropriate solid-tissue culture |
| 88235 | Tissue culture, amniotic fluid/chorionic villus cells | Prenatal cytogenetic culture |
| 88237 | Tissue culture for neoplastic disorders, bone marrow/blood cells | Oncology/hematologic cytogenetics |
| 88239 | Tissue culture, solid tumor | Tumor cytogenetics |
| CPT Code | Service | Billing Significance |
|---|---|---|
| 88261 | Chromosome analysis; 5 cells, 1 karyotype, with banding | Limited chromosome analysis |
| 88262 | Chromosome analysis; 15-20 cells, 2 karyotypes, with banding | Commonly used for constitutional chromosome analysis |
| 88263 | Chromosome analysis; 45 cells for mosaicism, 2 karyotypes, with banding | Mosaicism evaluation |
| 88264 | Chromosome analysis; analyze 20-25 cells | Commonly relevant to acquired/neoplastic analysis |
| 88267 | Amniotic fluid/chorionic villus; 15 cells, 1 karyotype, with banding | Prenatal chromosome analysis |
| 88269 | In situ amniotic fluid analysis; cells from 6-12 colonies, 1 karyotype, with banding | Prenatal in-situ analysis |
| 88280 | Additional karyotypes, each study | Add-on when additional karyotypes are supported |
| 88283 | Additional specialized banding technique | Add-on for specialized banding |
| 88285 | Additional cells counted, each study | Add-on for additional cell counting |
| 88289 | Additional high-resolution study | Add-on for high-resolution chromosome study |
| 88291 | Cytogenetics and molecular cytogenetics, interpretation and report | Interpretation/reporting; Medicare MUE = 1 |
The most common standalone chromosome analysis code is CPT 88262 for a routine 15-to-20-cell study with two karyotypes. But a real karyotyping claim often pairs 88262 (or 88264, 88267, 88269, depending on specimen type) with a tissue culture code and 88291 for interpretation, when each component is separately performed and reportable.
Billing Alert: Multiple services in a cytogenetics workflow do not mean every corresponding CPT code belongs on the claim. Report each service only when it was actually performed, separately reportable, and supported by the documentation and applicable payer rules.
These codes look similar but are not interchangeable, and the difference goes beyond cell count. It’s one of the most common coding judgment calls in cytogenetics.
CPT 88262 involves chromosome analysis of 15 to 20 cells with two banded karyotypes prepared. Typically billed for constitutional chromosome studies, this code is used when peripheral blood or fibroblast samples are tested to look for inherited chromosomal abnormalities.
When chromosome analysis covers 20 to 25 cells, labs report CPT 88264. This code generally appears on bone marrow or tumor studies tied to neoplastic or acquired conditions, as long as the chart notes support the testing performed.
Selecting the correct code depends on the type and purpose of the chromosome analysis, not simply on how many cells were reviewed. Reporting 88264 when documentation doesn’t support it creates an upcoding risk. Reporting 88262 when the service supports 88264 leaves legitimate reimbursement unclaimed.
Avoid the temptation to choose CPT 88264 just because “more cells = higher-paying code.” Documentation should always support the actual analysis performed.
Medicare may cover karyotyping when the service is reasonable and necessary and meets applicable Medicare coverage requirements. NCD 190.3 identifies specific covered indications for cytogenetic studies, including:
Local coverage requirements and applicable billing policies may also affect payment. If the laboratory expects Medicare not to cover a service because it’s not reasonable and necessary, an ABN may be required when the applicable Medicare rules allow beneficiary liability to be assigned. Labs should verify the applicable Medicare coverage and ABN requirements before testing rather than treating the ABN as a complete solution for every noncovered diagnosis.
| Underpayment Cause | Why It Happens | Fix |
|---|---|---|
| Missing add-on codes | The lab runs extra karyotypes, specialized banding, additional cell counts, or high-resolution studies, but the billing team never checks whether those services qualify for add-on codes. | Create a checklist that reviews the lab report before submission and catches any documented add-on services. |
| Incomplete or improperly authorized test requests | Ordering physician authorization or diagnosis is missing | Verify requisitions before accessioning; ensure proper authorization per CLIA |
| Mismatched CPT-ICD-10 pairing | Diagnosis code doesn't support the CPT billed | Cross-check against payer LCD/NCD coverage lists before submission |
| NCCI bundling denials | Code pairs trigger a Procedure-to-Procedure edit | Confirm modifier indicator before appending modifier 59, and only when clinically distinct |
| Frequency limits (MUEs) | Units billed exceed the Medically Unlikely Edit cap | Track MUE values per code and split studies accurately across specimens |
Important 2026 NCCI Point: CMS assigns an MUE (Medically Unlikely Edit) of 1 to CPT 88291. For Medicare claims, CMS interprets 88291 as encompassing the synthesis, interpretation, and report of cytogenetic/molecular cytogenetic testing performed on the same date of service. Don’t automatically report multiple units based on the number of specimens or tests.
An NCCI denial and a medical necessity denial aren’t the same. NCCI edits primarily address correct coding and code-pair reporting rather than determining whether a service is medically necessary or covered, so a bundling denial won’t automatically shift liability to the patient through an ABN. Confusing the two during an appeal wastes time and often gets the appeal returned to you. A modifier should never be used simply to force payment through an NCCI edit. It must be supported by the edit’s modifier indicator and the clinical circumstances documented for the service.
This point is extremely important when considering reimbursement for karyotyping tests. The 2026 Clinical Laboratory Fee Schedule (CLFS) rules changed during the year. Under Section 6226 of the Consolidated Appropriations Act, 2026, CMS delayed the phase-in of CLFS payment reductions for clinical diagnostic laboratory tests (CDLTs) that are not advanced diagnostic laboratory tests (ADLTs).
There was no phase-in payment reduction in 2026. Beginning in 2027 through 2029, Medicare payment reductions resulting from the private-payor-rate methodology will be capped at 15% per year compared with the prior year’s payment amount.
The 2026 PAMA reporting period ran from May 1 through July 31, 2026, using applicable private-payor rate and volume data collected from January 1 through June 30, 2025. That reporting period has now ended, and the reported data will be used to inform the calculation of CLFS payment rates for 2027-2029.
For reimbursement forecasting, labs should use the latest CMS CLFS release rather than relying on a prior year’s rate. CMS publishes quarterly CLFS updates, so billing teams should verify the applicable rate before finalizing reimbursement projections.
Once paid, the team reconciles the payment against the expected CLFS or contracted rate to catch underpayments early rather than months later during an annual audit.
Every one of those ten steps is a place where a karyotyping claim can quietly lose money. That’s exactly why cytogenetics billing benefits from dedicated laboratory RCM services instead of being a part of a lab’s general coding queue.
Denial prevention with good denial management services for labs beats appeal chasing every single time.
Not sure whether underpayment is quietly draining your revenue? Ask yourself these questions:
If you aren’t sure, it’s worth a formal revenue cycle audit.
Karyotyping billing isn’t like billing a basic metabolic panel. It requires expertise from coders who understand the difference between a 15-cell count and a 45-cell mosaicism study, track quarterly CLFS updates, and know how to appeal an NCCI bundling denial without confusing it for a medical necessity dispute. That’s a lot for an in-house team already occupied with a full test menu.
This is where a specialized molecular diagnostics billing partner, like TransLabs, can add practical value. A dedicated partner brings:
For smaller labs without dedicated cytogenetics coding expertise, outsourcing can provide specialized coding, denial management, payer-policy monitoring, and payment reconciliation without requiring the lab to build those capabilities entirely in-house.
Karyotyping billing rewards precision and punishes shortcuts. Get the tissue culture, chromosome analysis, and interpretation codes reported correctly, only when each is separately supported by documentation and applicable coding rules. Further, keep test requests complete and stay current with CLFS updates. These steps can significantly reduce avoidable denials and underpayments.
For labs that don’t have the bandwidth to track every NCCI edit and payer policy shift in-house, partnering with an experienced molecular diagnostics billing services team can turn a leaky revenue cycle into a predictable one.